Mesoblast Limited (MESO) vs uniQure N.V. (QURE)
- Mesoblast Limited MESO 13.21 +0.84%
- uniQure N.V. QURE 24.09 −2.19%
Mesoblast Limited and uniQure N.V. are both Biotechnology companies. Mesoblast Limited and uniQure N.V. are of similar size ($1.7B and $1.7B). uniQure N.V. grew revenue faster over the last twelve months: 28.0% against −26.5%. Mesoblast Limited has the higher net margin (−1,091.7% vs −1,154.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Mesoblast Limited leads on 11 and uniQure N.V. on 6.
Valuation
Profitability
| Metric | MESO | QURE | Biotechnology median |
|---|---|---|---|
| Gross margin | (269.72%) | 93.85% | 67.24% |
| Operating margin | (826.28%) | (1,001.74%) | 0.00% |
| Net margin | (1,091.71%) | (1,154.84%) | 0.00% |
| Free cash flow margin | 0.00% | (956.80%) | 0.00% |
| Return on equity | 0.00% | (88.99%) | (50.28%) |
| Return on assets | 0.00% | (25.47%) | (45.89%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack